Compile Data Set for Download or QSAR
maximum 50k data
Found 149 Enz. Inhib. hit(s) with all data for entry = 7812
TargetReceptor tyrosine-protein kinase erbB-4(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM50357312(IBRUTINIB | PCI-32765 | US10124003, Ref. Ex. Compo...)
Affinity DataIC50:  0.100nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase Blk(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM97672(US8476284, 40 | US9133201, 10 | US9181263, 9 | US9...)
Affinity DataIC50:  0.200nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM191606(US9181263, 23 | US9278100, 23)
Affinity DataIC50:  0.320nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM191605(US9181263, 14 | US9278100, 14)
Affinity DataIC50:  0.390nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase Fgr(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM97672(US8476284, 40 | US9133201, 10 | US9181263, 9 | US9...)
Affinity DataIC50:  0.400nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetEpidermal growth factor receptor(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM50357312(IBRUTINIB | PCI-32765 | US10124003, Ref. Ex. Compo...)
Affinity DataIC50:  0.5nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
TargetTyrosine-protein kinase Blk(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM50357312(IBRUTINIB | PCI-32765 | US10124003, Ref. Ex. Compo...)
Affinity DataIC50:  0.5nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM50357312(IBRUTINIB | PCI-32765 | US10124003, Ref. Ex. Compo...)
Affinity DataIC50:  0.5nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM50357312(IBRUTINIB | PCI-32765 | US10124003, Ref. Ex. Compo...)
Affinity DataIC50:  0.5nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM50357312(IBRUTINIB | PCI-32765 | US10124003, Ref. Ex. Compo...)
Affinity DataIC50:  0.5nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM191617(US9181263, 13 | US9278100, 13)
Affinity DataIC50:  0.670nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase Lck(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM220129(US9278100, 18)
Affinity DataIC50:  0.760nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCytoplasmic tyrosine-protein kinase BMX(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM50357312(IBRUTINIB | PCI-32765 | US10124003, Ref. Ex. Compo...)
Affinity DataIC50:  0.800nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase Yes(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM97672(US8476284, 40 | US9133201, 10 | US9181263, 9 | US9...)
Affinity DataIC50:  0.800nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase Lck(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM191614(US9181263, 10 | US9278100, 10)
Affinity DataIC50:  0.880nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM191628(US9181263, 24 | US9278100, 24)
Affinity DataIC50:  0.890nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM220128(US9278100, 11)
Affinity DataIC50:  0.920nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase HCK(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM97672(US8476284, 40 | US9133201, 10 | US9181263, 9 | US9...)
Affinity DataIC50:  1nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase Lck(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM97672(US8476284, 40 | US9133201, 10 | US9181263, 9 | US9...)
Affinity DataIC50:  1nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM97672(US8476284, 40 | US9133201, 10 | US9181263, 9 | US9...)
Affinity DataIC50:  1nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM97672(US8476284, 40 | US9133201, 10 | US9181263, 9 | US9...)
Affinity DataIC50:  1nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase Lck(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM97672(US8476284, 40 | US9133201, 10 | US9181263, 9 | US9...)
Affinity DataIC50:  1nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM97675(US8476284, 43 | US8497277, 15 | US9133201, 15 | US...)
Affinity DataIC50:  1.10nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCytoplasmic tyrosine-protein kinase BMX(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM97672(US8476284, 40 | US9133201, 10 | US9181263, 9 | US9...)
Affinity DataIC50:  1.10nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase Lyn(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM97672(US8476284, 40 | US9133201, 10 | US9181263, 9 | US9...)
Affinity DataIC50:  1.20nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM191614(US9181263, 10 | US9278100, 10)
Affinity DataIC50:  1.31nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM191616(US9181263, 12 | US9278100, 12)
Affinity DataIC50:  1.33nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM220129(US9278100, 18)
Affinity DataIC50:  1.38nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM191613(US9181263, 8 | US9278100, 8)
Affinity DataIC50:  1.40nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase Lck(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM191617(US9181263, 13 | US9278100, 13)
Affinity DataIC50:  1.56nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM191626(US9181263, 22 | US9278100, 22)
Affinity DataIC50:  1.57nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM191623(US9181263, 19 | US9278100, 19)
Affinity DataIC50:  1.58nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM191621(US9181263, 17 | US9278100, 17)
Affinity DataIC50:  2nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase Lck(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM50357312(IBRUTINIB | PCI-32765 | US10124003, Ref. Ex. Compo...)
Affinity DataIC50:  2nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase Lck(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM50357312(IBRUTINIB | PCI-32765 | US10124003, Ref. Ex. Compo...)
Affinity DataIC50:  2nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase Lck(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM191621(US9181263, 17 | US9278100, 17)
Affinity DataIC50:  2.07nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase CSK(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM50357312(IBRUTINIB | PCI-32765 | US10124003, Ref. Ex. Compo...)
Affinity DataIC50:  2.20nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetEpidermal growth factor receptor(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM191605(US9181263, 14 | US9278100, 14)
Affinity DataIC50:  2.30nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase Fgr(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM50357312(IBRUTINIB | PCI-32765 | US10124003, Ref. Ex. Compo...)
Affinity DataIC50:  2.30nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase CSK(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM97672(US8476284, 40 | US9133201, 10 | US9181263, 9 | US9...)
Affinity DataIC50:  2.40nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase Lck(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM220128(US9278100, 11)
Affinity DataIC50:  2.43nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase Lck(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM191612(US9181263, 7 | US9278100, 7)
Affinity DataIC50:  2.60nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM97678(US8476284, 9 | US8497277, 10 | US8497277, 9 | US91...)
Affinity DataIC50:  3.10nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM191620(US9181263, 16 | US9278100, 16)
Affinity DataIC50:  3.14nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetReceptor tyrosine-protein kinase erbB-4(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM97672(US8476284, 40 | US9133201, 10 | US9181263, 9 | US9...)
Affinity DataIC50:  3.20nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetProtein-tyrosine kinase 6(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM50357312(IBRUTINIB | PCI-32765 | US10124003, Ref. Ex. Compo...)
Affinity DataIC50:  3.30nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetProtein-tyrosine kinase 6(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM97672(US8476284, 40 | US9133201, 10 | US9181263, 9 | US9...)
Affinity DataIC50:  3.30nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM191629(US9181263, 25 | US9278100, 25)
Affinity DataIC50:  3.48nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase HCK(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM50357312(IBRUTINIB | PCI-32765 | US10124003, Ref. Ex. Compo...)
Affinity DataIC50:  3.70nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase Lck(Homo sapiens (Human))
Pharmacyclics

US Patent
LigandPNGBDBM191620(US9181263, 16 | US9278100, 16)
Affinity DataIC50:  3.82nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
In DepthDetails US Patent
Displayed 1 to 50 (of 149 total ) | Next | Last >>
Jump to: